Lynch Syndrome is the most common form of hereditary colorectal cancer.
By implementing Lynch syndrome pathways nationally for both colorectal and endometrial cancer there is the opportunity to detect many of these at an earlier stage and also prevent cancers through risk reduction treatments and appropriate surveillance routes.
Guidance on management of Lynch syndrome published by NHS UK (July 2021).
Click to access B0622-implementing-lynch-syndrome-testing-and-surveillance-pathways.pdf
Men carrying MSH2 and MSH6 pathogenic variants, which are associated with Lynch syndrome, were found to have a higher incidence of prostate cancer compared with age-matched non-carrier individuals, supporting the value of annual, targeted prostate-specific antigen (PSA) screening from age 40 to identify men with clinically significant prostate cancer, according to the initial results of the IMPACT study (NCT00261456) that were published in The Lancet Oncology.1
Conclusions: Familial burden – in addition to age, sex, and specific LS gene – should be used to assess LS carriers’ risks of specific cancers and guide decision-making about organ-specific surveillance.
“Some say, ‘Oh, I don’t want to know.’ And I think, well, you’re nuts because knowledge is power, and you can stay ahead of this,”
Bren has Lynch Syndrome and is constantly trying to create awareness.
Before and after his scan…..
Dr @AliceLeBonniec from @nuigalway and Dr Nick Clarke from @DCU are looking to recruit patient and public involvement contributors to help design two @IrishCancerSoc research studies to improve colorectal cancer screening uptake. More details above!
IS NOT finding out you have Cancer.
Finding out you have Lynch Syndrome…
IS A WAY TO PREVENT CANCER.
Lynch Syndrome Ireland 